Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management

Bibliography

• BLUM RH, CARTER SK: Adriamycin. A new anticancer drug with significant clinical activity. Ann. Intern. Med. (1974) 80(2):249-259.
   PubMed Web of Science ®Google Scholar
• LIPSHULTZ SE, SALLAN SE: Cardiovascular abnormalities in long-term survivors of childhood cancer. J. Clin. Oncol. (1993) 11:1199-1203.
   PubMed Web of Science ®Google Scholar
• HINKLE AS, PROUKOU CB, DESHPANDE SS et al.: Cardiotoxicity caused by chemotherapy. In: Late Effects of Childhood Cancer. Wallace WHB, Green DM (Eds). Edward Arnold, London. (2004):85-100.
   Google Scholar
• ADAMS MJ, DUFFY SA, CONSTINE LS, LIPSHULTZ SE: Cardiovascular effects of cancer therapy. In: Survivors of Childhood and Adolescent Cancer. Schwartz CL, Hobbie WL, Constine LS, Ruccione KS (Eds). Chapter 10. Springer-Verlag, Berlin-Heidelberg. (2005):133-159.
   Google Scholar
• TISMA-DUPANOVIC S, HARMON WG, ADAMS MJ et al.: Cancer therapy-related cardiotoxicities. In: Pediatric Heart Failure. Shaddy RE, Wernovsky G (Eds). Taylor & Francis, Boca Raton (2005):665-738.
   Google Scholar
• ALVAREZ JA, SCULLY RE, MILLER TL et al.: Late effects after treatment of childhood cancer. Curr. Opin. Pediatr. (2007) 19(1):23-31.
   PubMed Web of Science ®Google Scholar
• OEFFINGER KC, MERTENS AC, SKLAR CA et al.: Chronic health conditions in adult survivors of childhood cancer. N. Engl. J. Med. (2006) 355(15):1572-1582.
   PubMed Web of Science ®Google Scholar
• JEMAL A, SIEGEL R, WARD E et al.: Cancer statistics, 2006. CA Cancer J. Clin. (2006) 56(2):106-130.
   PubMed Web of Science ®Google Scholar
• RIES LA, HARKINS D, KRAPCHO M et al.: SEER Cancer Statistics Review, 1975-2003. National Cancer Institute, Bethesda, MD (2006).
   Google Scholar
• LEFRAK EA, PITHA J, ROSENHEIM S et al.: A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer (1973) 32(2):302-314.
   PubMed Web of Science ®Google Scholar
• PAI VB, NAHATA MC: Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf. (2000) 22(4):263-302.
   PubMed Web of Science ®Google Scholar
• ARCECI RJ: Surviving childhood cancer: a special series on the successes and challenges after ‘cure’. Pediatr. Blood Cancer (2006) 46(2):119-121.
   PubMed Web of Science ®Google Scholar
• BHATIA S, MEADOWS AT: Long-term follow-up of childhood cancer survivors: future directions for clinical care and research. Pediatr. Blood Cancer (2006) 46(2):143-148.
   PubMed Web of Science ®Google Scholar
• LANDIER W, WALLACE WH, HUDSON MM: Long-term follow-up of pediatric cancer survivors: education, surveillance, and screening. Pediatr. Blood Cancer (2006) 46(2):149-158.
   PubMed Web of Science ®Google Scholar
• FRIEDMAN DL, FREYER DR, LEVITT GA: Models of care for survivors of childhood cancer. Pediatr. Blood Cancer (2006) 46(2):159-168.
   PubMed Web of Science ®Google Scholar
• OEFFINGER KC, WALLACE WH: Barriers to follow-up care of survivors in the United States and the United Kingdom. Pediatr. Blood Cancer (2006) 46(2):135-142.
   PubMed Web of Science ®Google Scholar
• HAWKINS MM, ROBISON LL: Importance of clinical and epidemiological research in defining the long-term clinical care of pediatric cancer survivors. Pediatr. Blood Cancer (2006) 46(2):174-178.
   PubMed Web of Science ®Google Scholar
• GINSBERG JP, HOBBIE WL, CARLSON CA et al.: Delivering long-term follow-up care to pediatric cancer survivors: transitional care issues. Pediatr. Blood Cancer (2006) 46(2):169-173.
   PubMed Web of Science ®Google Scholar
• MERTENS AC, YASUI Y, NEGLIA JP et al.: Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J. Clin. Oncol. (2001) 19(13):3163-3172.
   PubMed Web of Science ®Google Scholar
• MOLLER TR, GARWICZ S, BARLOW L et al.: Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries. J. Clin. Oncol. (2001) 19:3173-3181.
   PubMed Web of Science ®Google Scholar
• KRISCHER JP, EPSTEIN S, CUTHBERTSON DD et al.: Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J. Clin. Oncol. (1997) 15(4):1544-1552.
   PubMed Web of Science ®Google Scholar
• SILVERMAN LB, DECLERCK L, GELBER RD et al.: Results of the Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia (2000) 14:2247-2256.
   PubMed Web of Science ®Google Scholar
• LIPSHULTZ SE, SANDERS SP, GOORIN A, KRISCHER JP, SALLAN SE, COLAN SD: Monitoring for anthracycline cardiotoxicity. Pediatrics (1994) 93:433-437.
   PubMed Web of Science ®Google Scholar
• GRENIER MA, LIPSHULTZ SE: Epidemiology of anthracycline cardiotoxicity in children and adults. Semin. Oncol. (1998) 25(4 Suppl. 10):72-85.
   PubMed Web of Science ®Google Scholar
• ADAMS MJ, LIPSHULTZ SE: Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention. Pediatr. Blood Cancer (2005) 44(7):600-606.
   PubMed Web of Science ®Google Scholar
• STEINBERG JS, COHEN AJ, WASSERMAN AG et al.: Acute arrhythmogenicity of doxorubicin administration. Cancer (1987) 60(6):1213-1218.
   PubMed Web of Science ®Google Scholar
• FRISHMAN WH, SUNG HM, YEE HC et al.: Cardiovascular toxicity with cancer chemotherapy. Curr. Probl. Cancer (1997) 21(6):301-360.
   PubMedGoogle Scholar
• GIANTRIS A, ABDURRAHMAN L, HINKLE A et al.: Anthracycline-induced cardiotoxicity in children and young adults. Crit. Rev. Oncol. Hematol. (1998) 27(1):53-68.
   PubMed Web of Science ®Google Scholar
• YEH ET, TONG AT, LENIHAN DJ et al.: Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation (2004) 109(25):3122-3131.
   PubMed Web of Science ®Google Scholar
• PRAGA C, BERETTA G, VIGO PL et al.: Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat. Rep. (1979) 63(5):827-834.
   PubMedGoogle Scholar
• GILLADOGA AC, MANUEL C, TAN CT et al.: The cardiotoxicity of adriamycin and daunomycin in children. Cancer (1976) 37(2 Suppl.):1070-1078.
   PubMed Web of Science ®Google Scholar
• LIPSHULTZ SE, LIPSITZ SR, SALLAN SE et al.: Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J. Clin. Oncol. (2005) 23(12):2629-2636.
   PubMed Web of Science ®Google Scholar
• LIPSHULTZ SE, COLAN SD, GELBER RD et al.: Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N. Engl. J. Med. (1991) 324(12):808-815.
   PubMed Web of Science ®Google Scholar
• VON HOFF DD, LAYARD MW, BASA P et al.: Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. (1979) 91(5):710-717.
   PubMed Web of Science ®Google Scholar
• SWAIN SM, WHALEY FS, EWER MS: Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer (2003) 97(11):2869-2879.
   PubMed Web of Science ®Google Scholar
• STEINHERZ LJ, STEINHERZ PG, TAN CT et al.: Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA (1991) 266(12):1672-1677.
   PubMed Web of Science ®Google Scholar
• VAN DALEN EC, VAN DER PAL HJH, KOK WEM, CARON HN, KREMER LCM: Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. Eur. J Cancer. (2006) 42:3191-3198.
   PubMed Web of Science ®Google Scholar
• ROBERT J, LE MORVAM V, SMITH D, POURQUIER P, BONNET J: Predicting drug response and toxicity based on gene polymorphisms. Crit. Rev. Oncol/Hematol. (2005) 54(3):171-196.
   PubMed Web of Science ®Google Scholar
• LIPSHULTZ SE, RIFAI N, SALLAN SE et al.: Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation (1997) 96:2641-2648.
   PubMed Web of Science ®Google Scholar
• KRISCHER JP, EPSTEIN S, CUTHBERTSON DD, GOORIN AM, EPSTEIN ML, LIPSHULTZ SE: Risk factors for early anthracycline cardiotoxicity in children: the pediatric oncology group experience. Prog. Pediatr. Cardiol. (1998) 8:83-90.
   Web of Science ®Google Scholar
• NYSOM K, COLAN SD, LIPSHULTZ SE: Late cardiotoxicity following anthracycline therapy for childhood cancer. Prog. Pediatr. Cardiol. (1998) 8:121-138.
   Web of Science ®Google Scholar
• SHEPHERD LE, PARULEKAR W, PRITCHARD KI et al.: Left ventricular function following adjuvant chemotherapy for breast cancer: the NCIC CTG MA5 experience. J. Clin. Oncol. (2006) 24(18S):522.
   PubMed Web of Science ®Google Scholar
• FUMOLEAU P, ROCHE H, KERBRAT P et al.: Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann. Oncol. (2006) 17(1):85-92.
   PubMed Web of Science ®Google Scholar
• LIPSHULTZ SE, LIPSITZ SR, MONE SM et al.: Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N. Engl. J. Med. (1995) 332(26):1738-1743.
   Google Scholar
• SIMBRE VC II, DUFFY SA, DADLANI GH, MILLER TL, LIPSHULTZ SE: Cardiotoxicity of cancer chemotherapy: implications for children. Pediatric Drugs (2005) 7(3):187-202.
   PubMedGoogle Scholar
• LIPSHULTZ SE, LOPEZ-MITNIK G, ADAMS MJ et al.: Cardiovascular status, subsequent risk, and associated factors in long-term survivors of childhood cancer in a population-based NCI study. Circulation (2006) 112(17 Suppl. 2):II-476.
   Google Scholar
• CHOW AY, CHIN C, DAHL G et al.: Anthracyclines cause endothelial injury in pediatric cancer patients: a pilot study. J. Clin. Oncol. (2006) 24(6):925-928.
   PubMed Web of Science ®Google Scholar
• HORTOBAGYI GN: Anthracyclines in the treatment of cancer. An overview. Drugs (1997) 54(Suppl. 4):1-7.
   PubMed Web of Science ®Google Scholar
• BILLINGHAM ME, MASON JW, BRISTOW MR et al.: Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat. Rep. (1978) 62(6):865-872.
   PubMedGoogle Scholar
• BERRY GJ, JORDEN M: Pathology of radiation and anthracycline cardiotoxicity. Pediatr. Blood Cancer. (2005) 44(7):630-637.
   PubMed Web of Science ®Google Scholar
• OWAN TE, HODGE DO, HERGES RM et al.: Trends in prevalence and outcome of heart failure with preserved ejection fraction. N. Engl. J. Med. (2006) 355:251-259.
   PubMed Web of Science ®Google Scholar
• BHATIA RS, TU JV, LEE DS et al.: Outcomes of heart failure with preserved ejection fraction in a population-based study. N. Engl. J. Med. (2006) 355:260-269.
   PubMed Web of Science ®Google Scholar
• NYSOM K, HOLM K, LIPSITZ SR et al.: Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J. Clin. Oncol. (1998) 16(2):545-550.
   PubMed Web of Science ®Google Scholar
• ADAMS MJ, LIPSITZ SR, COLAN SD et al.: Cardiovascular status in long-term survivors of Hodgkin’s disease treated with chest radiotherapy. J. Clin. Oncol. (2004) 22:3139-3148.
   PubMed Web of Science ®Google Scholar
• CONSTINE LS, HINKLE AS, FRENCH CA et al.: Radiation-associated risk factors for premature cardiovascular disease in childhood cancer survivors include accelerated atherosclerosis. Int. J. Radiat. Oncol. Biol. Phys. (2003) 57(2 Suppl.):S199-S200.
   Google Scholar
• VAN DALEN EC, VAN DER PAL HJ, CARON HN, KREMER LC: Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst. Rev. (2006) 4:CD005008.
   Google Scholar
• VAN DALEN EC, MICHIELS EM, CARON HN, KREMER LC: Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst. Rev. (2006) 4:CD005006.
   Google Scholar
• HORENSTEIN MS, VANDER HEIDE RS, L’ECUYER TJ: Molecular basis of anthracycline-induced cardiotoxicity and its prevention. Mol. Genet. Metab. (2000) 71(1-2):436-444.
   PubMed Web of Science ®Google Scholar
• GEWIRTZ DA: A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. (1999) 57(7):727-741.
   PubMed Web of Science ®Google Scholar
• MINOTTI G, MENNA P, SALVATORELLI E, CAIRO G, GIANNI L: Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. (2004) 56:185-229.
   PubMed Web of Science ®Google Scholar
• SCHIMMEL KJ, RICHEL DJ, VAN DEN BRINK RB et al.: Cardiotoxicity of cytotoxic drugs. Cancer Treat. Rev. (2004) 30(2):181-191.
   PubMed Web of Science ®Google Scholar
• LINK G, PINSON A, HERSHKO C: Iron loading of cultured cardiac myocytes modifies sarcolemmal structure and increases lysosomal fragility. J. Lab. Clin. Med. (1993) 121(1):127-134.
   PubMed Web of Science ®Google Scholar
• HERSHKO C, LINK G, TZAHOR M et al.: Anthracycline toxicity is potentiated by iron and inhibited by deferoxamine: studies in rat heart cells in culture. J. Lab. Clin. Med. (1993) 122(3):245-251.
   PubMed Web of Science ®Google Scholar
• KWOK JC, RICHARDSON DR: The cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracycline-mediated cardiotoxicity. Redox. Rep. (2000) 5(6):317-324.
   PubMed Web of Science ®Google Scholar
• HERSHKO CA, PINSON A, LINK G: Prevention of anthracycline cardiotoxicity by iron chelation. Acta Haematol. (1996) 95(1):87-92.
   PubMed Web of Science ®Google Scholar
• ITO H, MILLER SC, BILLINGHAM ME et al.: Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc. Natl. Acad. Sci. USA (1990) 87:4275-4279.
   PubMed Web of Science ®Google Scholar
• OLSON RD, MUSHLIN PS: Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J. (1990) 4:3076-3086.
   PubMed Web of Science ®Google Scholar
• PENG X, CHEN B, LIM CC et al.: The cardiotoxicity of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine. Molecular Interventions (2005) 5:163-171.
   PubMed Web of Science ®Google Scholar
• WALLACE KB: Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol. Toxicol. (2003) 93:105-115.
   PubMedGoogle Scholar
• LEBRECHT D, SETZER B, KETELSEN U-P, HABERSTROH J, WALKER UA: Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation (2003) 108:2423-2429.
   PubMed Web of Science ®Google Scholar
• LEBRECHT D, KOKKORI A, KETELSEN U-P, SETZER B, WALKER UA: Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin. J. Pathol. (2005) 207:436-444.
   PubMed Web of Science ®Google Scholar
• EWER MS, LIPPMAN SM: Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J. Clin. Oncol. (2005) 23(13):2900-2902.
   PubMed Web of Science ®Google Scholar
• KEEFE DL: Trastuzumab-associated cardiotoxicity. Cancer (2002) 95(7):1592-1600.
   PubMed Web of Science ®Google Scholar
• PICCART-GEBHART MJ, PROCTER M, LEYLAND-JONES B et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. (2005) 353(16):1659-1672.
   PubMed Web of Science ®Google Scholar
• ROMOND EH, PEREZ EA, BRYANT J et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. (2005) 353(16):1673-1684.
   PubMed Web of Science ®Google Scholar
• JOENSUU H, PIRKKO-LIISA K-L, BONO P et al.: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. (2006) 354:809-820.
   PubMed Web of Science ®Google Scholar
• EWER MS, VOOLETICH MT, DURAND J-B et al.: Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J. Clin. Oncol. (2005) 223(31):7820-7826.
   Google Scholar
• TAN-CHIU E, YOTHERS G, ROMOND E et al.: Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J. Clin. Oncol. (2005) 23(31):7811-7819.
   PubMed Web of Science ®Google Scholar
• GUARNERI V, LENIHAN DJ, VALERO V et al.: Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J. Clin. Oncol. (2006) 24(25):4107-4115.
   PubMed Web of Science ®Google Scholar
• OZCELIK C, ERDMANN B, PILZ B et al.: Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc. Natl. Acad. Sci. USA (2002) 99(13):8880-8885.
   PubMed Web of Science ®Google Scholar
• LEMMENS K, SEGERS VF, DEMOLDER M et al.: Role of neuregulin-1/ErbB2 signaling in endothelium-cardiomyocyte cross-talk. J. Biol. Chem. (2006) 281(28):19469-19477.
   PubMed Web of Science ®Google Scholar
• CHIEN KR: Herceptin and the heart-a molecular modifier of cardiac failure. N. Engl. J. Med. (2006) 354(8):789-790.
   PubMed Web of Science ®Google Scholar
• CHIEN KR: Stress pathways and heart failure. Cell (1999) 98(5):555-558.
   PubMed Web of Science ®Google Scholar
• PEREZ E, BYRNE JA, HAMMOND IW et al.: Cardiac safety experience in 3127 patients (pts) treated with lapatinib. Ann. Oncol. (2006) 17(Suppl.):ix70.
   Google Scholar
• KERKELA R, GRAZETTE L, YACOBI R et al.: Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. (2006) 12(8):908-916.
   PubMed Web of Science ®Google Scholar
• WOUTERS KA, KREMER LC, MILLER TL et al.: Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br. J. Haematol. (2005) 131(5):561-578.
   PubMed Web of Science ®Google Scholar
• VAN DALEN EC, CARON HN, DICKINSON HO, KREMER LC: Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. (2005) (1):CD003917.
   Google Scholar
• LIPSHULTZ SE, GIANTRIS AL, LIPSITZ SR et al.: Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J. Clin. Oncol. (2002) 20(6):1677-1682.
   PubMed Web of Science ®Google Scholar
• LEGHA SS, BENJAMIN RS, MACKAY B et al.: Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann. Intern. Med. (1982) 96(2):133-139.
   PubMed Web of Science ®Google Scholar
• EWER MS, MARTIN FJ, HENDERESON C, SHAPIRO CL, BENJAMIN RS, GABIZON AA: Cardiac safety of liposomal anthracyclines. Semin. Oncol. (2004) 31(Suppl. 13):161-181.
   PubMed Web of Science ®Google Scholar
• GABIZON A, MARTIN F: Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs (1997) 54(Suppl. 4):15-21.
   PubMed Web of Science ®Google Scholar
• COUKELL AJ, SPENCER CM: Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi’s sarcoma. Drugs (1997) 53(3):520-538.
   PubMed Web of Science ®Google Scholar
• STEWART S, JABLONOWSKI H, GOEBEL FD et al.: Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J. Clin. Oncol. (1998) 16(2):683-691.
   PubMed Web of Science ®Google Scholar
• NORTHFELT DW, DEZUBE BJ, THOMMES JA et al.: Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi’s sarcoma: results of a randomized Phase III clinical trial. J. Clin. Oncol. (1998) 16(7):2445-2451.
   PubMed Web of Science ®Google Scholar
• O’BRIEN ME, WIGLER N, INBAR M et al.: Reduced cardiotoxicity and comparable efficacy in a Phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. (2004) 15(3):440-449.
   PubMed Web of Science ®Google Scholar
• HARRIS L, BATIST G, BELT R et al.: Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer (2002) 94(1):25-36.
   PubMed Web of Science ®Google Scholar
• GORDON AN, FLEAGLE JT, GUTHRIE D et al.: Recurrent epithelial ovarian carcinoma: a randomized Phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. (2001) 19(14):3312-3322.
   PubMed Web of Science ®Google Scholar
• BERRY G, BILLINGHAM M, ALDERMAN E et al.: The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi’s sarcoma patients treated with pegylated liposomal doxorubicin. Ann. Oncol. (1998) 9(7):711-716.
   PubMed Web of Science ®Google Scholar
• SAFRA T, MUGGIA F, JEFFERS S et al.: Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann. Oncol. (2000) 11(8):1029-1033.
   PubMed Web of Science ®Google Scholar
• THEODOULOU M, HUDIS C: Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin? Cancer (2004) 100(10):2052-2063.
   PubMed Web of Science ®Google Scholar
• CHIA S, CLEMONS M, MARTIN LA et al.: Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter Phase II trial. J. Clin. Oncol. (2006) 24(18):2773-2778.
   PubMed Web of Science ®Google Scholar
• LOWIS S, LEWIS I, ELSWORTH A et al.: A Phase I study of intravenous liposomal dunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours. Br. J. Cancer. (2006) 95:571-580.
   PubMed Web of Science ®Google Scholar
• GOLDIN A, VENDITTI JM, GERAN R: The effectiveness of the anthracycline analog 4’-epidoxorubicin in the treatment of experimental tumors: a review. Invest. New Drugs (1985) 3(1):3-21.
   PubMed Web of Science ®Google Scholar
• PLOSKER GL, FAULDS D: Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs (1993) 45(5):788-856.
   PubMed Web of Science ®Google Scholar
• JAIN KK, CASPER ES, GELLER NL et al.: A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J. Clin. Oncol. (1985) 3(6):818-826.
   PubMed Web of Science ®Google Scholar
• RYBERG M, NIELSEN D, SKOVSGAARD T et al.: Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J. Clin. Oncol. (1998) 16(11):3502-3508.
   PubMed Web of Science ®Google Scholar
• LAHTINEN R, KUIKKA J, NOUSIAINEN T et al.: Cardiotoxicity of epirubicin and doxorubicin: a double-blind randomized study. Eur. J. Haematol. (1991) 46(5):301-305.
   PubMed Web of Science ®Google Scholar
• MEINARDI MT, VAN VELDHUISEN DJ, GIETEMA JA et al.: Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J. Clin. Oncol. (2001) 19(10):2746-2753.
   PubMed Web of Science ®Google Scholar
• ROBERT J, RIGAL-HUGUET F, HURTELOUP P: Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients. Hematol. Oncol. (1992) 10(2):111-116.
   PubMed Web of Science ®Google Scholar
• MARTONI A, PIANA E, GUARALDI M et al.: Comparative Phase II study of idarubicin versus doxorubicin in advanced breast cancer. Oncology (1990) 47(5):427-432.
   PubMed Web of Science ®Google Scholar
• ANDERLINI P, BENJAMIN RS, WONG FC et al.: Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J. Clin. Oncol. (1995) 13(11):2827-2834.
   PubMed Web of Science ®Google Scholar
• SHENKENBERG TD, VON HOFF DD: Mitoxantrone: a new anticancer drug with significant clinical activity. Ann. Intern. Med. (1986) 105(1):67-81.
   PubMed Web of Science ®Google Scholar
• PRENTICE HG: The role of mitozantrone in the treatment of acute leukaemia. Acta Haematol. (1987) 78(Suppl. 1):136-138.
   PubMed Web of Science ®Google Scholar
• NEIDHART JA, GOCHNOUR D, ROACH R et al.: A comparison of mitoxantrone and doxorubicin in breast cancer. J. Clin. Oncol. (1986) 4(5):672-677.
   PubMed Web of Science ®Google Scholar
• COWAN JD, NEIDHART J, MCCLURE S et al.: Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study. J. Natl. Cancer Inst. (1991) 83(15):1077-1084.
   PubMedGoogle Scholar
• HENDERSON IC, ALLEGRA JC, WOODCOCK T et al.: Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J. Clin. Oncol. (1989) 7(5):560-571.
   PubMed Web of Science ®Google Scholar
• HOCHSTER S: Clinical pharmacology of dexrazoxane. Semin. Oncol. (1998) 25(4 Suppl. 10):37-42.
   PubMed Web of Science ®Google Scholar
• THOMAS C, VILE GF, WINTERBOURN CC: The hydrolysis product of ICRF-187 promotes iron-catalysed hydroxyl radical production via the Fenton reaction. Biochem. Pharmacol. (1993) 45(10):1967-1972.
   PubMed Web of Science ®Google Scholar
• CVETKOVIC RS, SCOTT LJ: Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy. Drugs (2005) 65(7):1005-1024.
   PubMed Web of Science ®Google Scholar
• SCHUCHTER LM, HENSLEY ML, MEROPOL NJ et al., AMERICAN SOCIETY OF CLINICAL ONCOLOGY CHEMOTHERAPY AND RADIOTHERAPY EXPERT PANEL: 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol. (2002) 20(12):2895-2903.
   PubMed Web of Science ®Google Scholar
• LIPSHULTZ SE, RIFAI N, DALTON VM et al.: The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N. Engl. J. Med. (2004) 351(2):145-153.
   PubMed Web of Science ®Google Scholar
• SWAIN SM, WHALEY FS, GERBER MC et al.: Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J. Clin. Oncol. (1997) 15(4):1318-1332.
   PubMed Web of Science ®Google Scholar
• LOPEZ M, VICI P, DI LAURO K et al.: Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J. Clin. Oncol. (1998) 16(1):86-92.
   PubMed Web of Science ®Google Scholar
• SPEYER JL, GREEN MD, KRAMER E et al.: Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N. Engl. J. Med. (1988) 319(12):745-752.
   PubMed Web of Science ®Google Scholar
• SWAIN SM, WHALEY FS, GERBER MC et al.: Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J. Clin. Oncol. (1997) 15(4):1333-1340.
   PubMed Web of Science ®Google Scholar
• SWAIN SM, VICI P: The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J. Cancer Res. Clin. Oncol. (2004) 130(1):1-7.
   PubMed Web of Science ®Google Scholar
• MARTY M, ESPIE M, LLOMBART A et al.: Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann. Oncol. (2006) 17:614-622.
   PubMed Web of Science ®Google Scholar
• HELLMANN K: Dexrazoxane and the ASCO guidelines for the use of chemotherapy and radiotherapy protectants: a critique. J. Clin. Oncol. (2000) 18(9):2004-2006.
   PubMed Web of Science ®Google Scholar
• BATES M, LIEU D, ZAGARI M, SPIERS A, WILLIAMSON T: A pharmacoeconomic evaluation of the use of dexrazoxane in preventing anthracycline-induced cardiotoxicity in patients with stage IIIB or IV metastatic breast cancer. Clin. Ther. (1997) 19(1):167-184.
   PubMed Web of Science ®Google Scholar
• LIPSHULTZ SE: Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children. J. Clin. Oncol. (1996) 14(2):328-331.
   PubMed Web of Science ®Google Scholar
• WEXLER LH, ANDRICH MP, VENZON D et al.: Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J. Clin. Oncol. (1996) 14(2):362-372.
   PubMed Web of Science ®Google Scholar
• MOGHRABI A, LEVY DE, ASSELIN B et al.: Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. (2007) 109(3):896-904.
   PubMed Web of Science ®Google Scholar
• TEBBI CK, LONDON WB, FRIEDMAN D et al.: Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin’s disease. J. Clin. Oncol. (2007) 25(5):493-500.
   PubMed Web of Science ®Google Scholar
• IARUSSI D, AURICCHIO U, AGRETTO A et al.: Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Mol. Aspects Med. (1994) 15(Suppl.):s207-s212.
   PubMed Web of Science ®Google Scholar
• DE LEONARDIS V, DE SCALZI M, NERI B, BARTALUCCI S, CINELLI P: Echocardiographic assessment of anthracycline cardiotoxicity during different therapeutic regimens. Int. J. Clin. Pharmacol. Res. (1987) 7(4):307-311.
   PubMedGoogle Scholar
• MYERS C, BONOW R, PALMERI S et al.: A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin. Oncol. (1983) 10(1 Suppl. 1):53-55.
   PubMed Web of Science ®Google Scholar
• UNVERFERTH DV, MEHEGAN JP, NELSON RW et al.: The efficacy of N-acetylcysteine in preventing doxorubicin-induced cardiomyopathy in dogs. Semin. Oncol. (1983) 10(1 Suppl. 1):2-6.
   PubMedGoogle Scholar
• QUILES JL, HUERTAS JR, BATTINO M et al.: Antioxidant nutrients and adriamycin toxicity. Toxicology (2002) 180(1):79-95.
   PubMed Web of Science ®Google Scholar
• SIVESKI-ILISKOVIC N, HILL M, CHOW DA, SINGAL PK: Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation (1995) 91(1):10-15.
   PubMed Web of Science ®Google Scholar
• ELIHU N, ANANDASBAPATHY S, FRISHMAN WH: Chelation therapy in cardiovascular disease: ethylenediaminetetraacetic acid, desferoxamine, and dexrazoxane. J. Clin. Pharmacol. (1998) 38(2):101-105.
   PubMed Web of Science ®Google Scholar
• BJELAKOVIC G, NIKOLOVA D, GLUUD LL et al.: Mortality in randomized trials of antioxidant supplements for primary and secondary prevention systematic review and meta-analysis. JAMA (2007) 297:842-857.
   PubMed Web of Science ®Google Scholar
• BAZZABI LA, REYNOLDS K, HOLDER KN et al.: Effect of folic acid supplementation on risk of cardiovascular diseases. A meta-analysis of randomized controlled trials. JAMA (2006) 296:2720-2726.
   PubMed Web of Science ®Google Scholar
• HURLEY D: Diet supplements and safety: some disquieting data. New York Times (2007) January 16.
   Google Scholar
• CHEITLIN MD, ARMSTRONG WF, AURIGEMMA GP et al.: ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation (2003) 108:1146-1162.
   PubMed Web of Science ®Google Scholar
• KREMER LCM, TIEL-VAN BUUL MMC, UBBINK MC et al.: Indium-111-antimyosin scintigraphy in the early detection of heart damage after anthracycline therapy in children. J. Clin. Oncol. (1999) 17(4):1208-1211.
   PubMed Web of Science ®Google Scholar
• ANTMAN EM: Decision making with cardiac troponin tests. N. Engl. J. Med. (2002) 346(26):2079-2082.
   PubMed Web of Science ®Google Scholar
• LIPSHULTZ SE, SOMERS MJ, LIPSITZ SR, COLAN SD, JABS K, RIFAI N: Serum cardiac troponin and subclinical cardiac status in pediatric chronic renal failure. Pediatrics (2003) 112:79-86.
   PubMed Web of Science ®Google Scholar
• HERMAN EH, ZHANG J, RIFAI N: The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity. Cancer Chemother. Pharmacol. (2001) 48:297-304.
   PubMed Web of Science ®Google Scholar
• HERMAN EH, ZHANG J, LIPSHULTZ SE et al.: Correlation between serum levels of cardiac troponin –T and the severity of chronic cardiomyopathy induced by doxorubicin. J. Clin. Oncol. (1999) 17:2237-2243.
   PubMed Web of Science ®Google Scholar
• HERMAN EH, LIPSHULTZ SE, RIFAI N et al.: Cardiac troponin T: elevated serum levels and loss from cardiac myocytes in doxorubicin toxicity. Cancer Res. (1998) 58:195-197.
   PubMed Web of Science ®Google Scholar
• OTTLINGER M, PEARSALL L, RIFAI N, LIPSHULTZ SE: New developments in the biochemical assessment of myocardial injury in children: troponin T and I as highly sensitive and specific markers of myocardial injury. Prog. Pediatr. Cardiol. (1998) 8:71-81.
   Web of Science ®Google Scholar
• SIMBRE II VC, ADAMS MJ, DESHPANDE SS, DUFFY SA, MILLER TL, LIPSHULTZ SE: Cardiomyopathy caused by antineoplastic therapies. Curr. Treat. Options Cardiovasc. Med. (2001) 3(6):493-505.
   PubMedGoogle Scholar
• FRIED I, BAR-OZ B, ALGUR N et al.: Comparison of n-terminal pro-b-type natriuretic peptide levels in critically ill children with sepsis versus acute left ventricular dysfunction. Pediatrics (2006) 118:1165-1168.
   Google Scholar
• HUNT SA, ABRAHAM WT, CHIN MH et al.: ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association task force on evaluation and management of heart failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation (2005) 112:e154-e235.
   PubMed Web of Science ®Google Scholar
• ANONYMOUS: Executive summary: HFSA 2006 comprehensive heart failure practice guideline. J. Card. Fail. (2006) 12:10-38.
   PubMed Web of Science ®Google Scholar
• ROSENTHAL D, CHRISANT MR, EDENS E et al.: International society for heart and lung transplantation: practice guidelines for management of heart failure in children. J. Heart Lung Transplant. (2004) 23(12):1313-1333.
   PubMed Web of Science ®Google Scholar
• THE SOLVD INVESTIGATORS: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. (1991) 325(5):293-302.
   PubMed Web of Science ®Google Scholar
• THE SOLVD INVESTIGATORS: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N. Engl. J. Med. (1992) 327(10):685-691.
   PubMed Web of Science ®Google Scholar
• YUSUF S, SLEIGHT P, POGUE J, BOSCH J, DAVIES R, DAGENAIS G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. (2000) 342(3):145-153.
   PubMed Web of Science ®Google Scholar
• JONG P, YUSUF S, ROUSSEAU MF, AHN SA, BANGDIWALA SI: Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet (2003) 361(9372):1843-1848.
   PubMed Web of Science ®Google Scholar
• HUNT SA, BAKER DW, CHIN MH et al.: ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America. Circulation (2001) 104(24):2996-3007.
   PubMed Web of Science ®Google Scholar
• GRENIER MA, FIORAVANTI J, TRUESDELL SC, MENDELSOHN AM, VERMILION RP, LIPSHULTZ SE: Angiotensin-converting enzyme inhibitor therapy for ventricular dysfunction in infants, children and adolescents: a review. Prog. Pediatr. Cardiol. (2000) 12(1):91-111.
   PubMedGoogle Scholar
• SILBER JH: Role of afterload reduction in the prevention of late anthracycline cardiomyopathy. Pediatr. Blood Cancer (2005) 44(7):607-613.
   PubMed Web of Science ®Google Scholar
• SILBER JH, CNAAN A, CLARK BJ et al.: Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J. Clin. Oncol. (2004) 22(5):820-828.
   PubMed Web of Science ®Google Scholar
• LIPSHULTZ SE, LIPSITZ SR, SALLAN SE et al.: Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J. Clin. Oncol. (2002) 20(23):4517-4522.
   PubMed Web of Science ®Google Scholar
• LIPSHULTZ SE, COLAN SD: Cardiovascular trials in long-term survivors of childhood cancer. J. Clin. Oncol. (2004) 22(5):769-773.
   PubMed Web of Science ®Google Scholar
• CARDINALE D, COLOMBO A, SANDRI MT et al.: Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation (2006) 114:2474-2481.
   PubMed Web of Science ®Google Scholar
• SHADDY RE, OLSEN SL, BRISTOW MR et al.: Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients. Am. Heart J. (1995) 129(1):197-199.
   PubMed Web of Science ®Google Scholar
• NOORI A, LINDENFELD J, WOLFEL E, FERGUSON D, BRISTOW MR, LOWES BD: Beta-blockade in adriamycin-induced cardiomyopathy. J. Card. Fail. (2000) 6(2):115-119.
   PubMed Web of Science ®Google Scholar
• RUSCONI P, GOMEZ-MARIN O, ROSSIQUE-GONZALEZ M et al.: Carvedilol in children with cardiomyopathy: 3-year experience at a single institution. J. Heart Lung Transplant. (2004) 23:832-838.
   PubMed Web of Science ®Google Scholar
• BRUNS LA, CHRISANT MK, LAMOUR JM et al.: Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. J. Pediatr. (2001) 138:505-511.
   PubMed Web of Science ®Google Scholar
• WILLIAMS R, TANI L, SHADDY RE: Intermediate effects of treatment with metoprolol or carvedilol in children with left ventricular systolic dysfunction. J. Heart Lung Transplant. (2002) 21:906-909.
   PubMed Web of Science ®Google Scholar
• WAGONER LE, STARLING RC, O’CONNOR CM: Cardiac function and heart failure. J. Am. Col. Cardiol. (2006) 47(11 Suppl. D):D18-D22.
   Google Scholar
• OLIVEIRA PJ, BJORK JA, SANTOS MS et al.: Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicol. Appl. Pharmacol. (2004) 200(2):159-168.
   PubMed Web of Science ®Google Scholar
• KALAY N, BASAR E, OZDOGRU I et al.: Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J. Am. Coll. Cardiol. (2006) 48(11):2258-2262.
   PubMed Web of Science ®Google Scholar
• PFEFFER MA, SWEDBERG K, GRANGER CB et al.: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet (2003) 362(9386):759-766.
   PubMed Web of Science ®Google Scholar
• MCMURRAY JJ: Angiotensin inhibition in heart failure. J. Renin Angiotensin Aldosterone Syst. (2004) 5(Suppl. 1):S17-S22.
   PubMed Web of Science ®Google Scholar
• AKIMOTO H, BRUNO NA, SLATE DL, BILLINGHAM ME, TORTI SV, TORTI FM: Effect of verapamil on doxorubicin cardiotoxicity: altered muscle gene expression in cultured neonatal rat cardiomyocytes. Cancer Res. (1993) 53(19):4658-4664.
   PubMed Web of Science ®Google Scholar
• WIKMAN-COFFELT J, RAPCSAK M, SIEVERS R, ROULEAU JL, PARMLEY WW: Verapamil, propranolol, and hydralazine protect against the acute cardiac depression induced by adriamycin. Cardiovasc. Res. (1983) 17(1):43-49.
   PubMed Web of Science ®Google Scholar
• MILEI J, MARANTZ A, ALE J, VAZQUEZ A, BUCETA JE: Prevention of adriamycin-induced cardiotoxicity by prenylamine: a pilot double blind study. Cancer Drug Deliv. (1987) 4(2):129-136.
   PubMedGoogle Scholar
• KRAFT J, GRILLE W, APPELT M et al.: Effects of verapamil on anthracycline-induced cardiomyopathy: preliminary results of a prospective multicenter trial. Haematol. Blood Transfus. (1990) 33:566-570.
   PubMedGoogle Scholar
• LIPSHULTZ SE, VLACH SA, LIPSITZ SR, SALLAN SE, SCHWARTZ ML, COLAN SD: Cardiac changes associated with growth hormone therapy among children treated with anthracyclines. Pediatrics (2005) 115(6):1613-1622.
   PubMed Web of Science ®Google Scholar
• SALLAN SE, LIPSHULTZ SE: Wise up: do not do it without protection. Pediatr. Blood Cancer, (2005) 45:872-873.
   PubMed Web of Science ®Google Scholar
• DOYLE C, KUSHI LH, BYERS T et al.: Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. CA Cancer J. Clin. (2006) 56:323-353.
   PubMed Web of Science ®Google Scholar
• MILLER TL, HORGAN S, LIPSHULTZ SE: Exercise rehabilitation of pediatric patients with cardiovascular disease. Prog. Ped. Card. (2005) 20(1):27-37.
   Google Scholar
• CHIUVE SE, MCCULLOUGH ML, SACKS FM et al.: Healthy lifestyle factors in the primary prevention of coronary heart disease among men. Benefits among users and nonusers of lipid-lowering and antihypertensive medications. Circulation (2006) 114:160-167.
   PubMed Web of Science ®Google Scholar
• LANDIER W, BHATIA S, ESHELMAN DA et al.: Development of risk-based guidelines for pediatric cancer survivors: the Children’s Oncology Group Long-Term Follow-Up Guidelines from the Children’s Oncology Group Late Effects Committee and Nursing Discipline. J. Clin. Oncol. (2004) 22:4979-4990.
   PubMed Web of Science ®Google Scholar
• VAN DALEN EC, VEN DER PAL HJ, REITSMA JB et al.: Management of asymptomatic anthracycline-induced cardiac damage after treatment for childhood cancer: a postal survey among Dutch adult and pediatric cardiologists. J. Pediatr. Hematol. Oncol. (2005) 27(6):319-322.
   PubMed Web of Science ®Google Scholar
• HINKLE AS, PROUKOU C, FRENCH CA et al.: A clinic-based, comprehensive care model for studying late effects in long-term survivors of pediatric illnesses. Pediatrics (2004) 113(4 Suppl.):1141-1145.
   PubMed Web of Science ®Google Scholar